Results 271 to 280 of about 326,057 (302)
Some of the next articles are maybe not open access.
Seminars in cancer biology, 1993
Tyrosine kinases are associated with the cytoplasmic domains of growth factor receptors as well as oncoproteins and many have the potential to cause transformation if mutated or hyperexpressed. Tyrosine kinases therefore represent an excellent target for the development of cancer drugs.
P, Workman, V G, Brunton, D J, Robins
openaire +1 more source
Tyrosine kinases are associated with the cytoplasmic domains of growth factor receptors as well as oncoproteins and many have the potential to cause transformation if mutated or hyperexpressed. Tyrosine kinases therefore represent an excellent target for the development of cancer drugs.
P, Workman, V G, Brunton, D J, Robins
openaire +1 more source
Tyrosine Kinase Inhibitors in Pediatric Malignancies
Cancer Investigation, 2007Tyrosine kinase inhibitors have been used to treat adult cancers for over a decade. Since the discovery of imatinib mesylate (STI-571, Gleevec; Novartis), tyrosine kinase inhibitors have ushered in a new age of targeted therapy. Although the United States Food and Drug Administration has approved several kinase inhibitors for use in adult cancers ...
Jeffrey M, Skolnik, Peter C, Adamson
openaire +2 more sources
CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases
Multiple Sclerosis Journal, 2020Dalia L Rotstein +2 more
exaly
Resistance to Bruton Tyrosine Kinase Inhibitors
Hematology/Oncology Clinics of North AmericaTargeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire +2 more sources